Epidermolysis Bullosa — Pipeline Review, H1 2015

1
Epidermolysis Bullosa - Pipeline Review, H1 2015
(Type, Mode of action, Crop Type and Geography) -
Size, Share, Global Trends, Company Profiles,
Demand, Insights, Analysis, Research, Report,
Opportunities, Segmentation and Forecast, 2013 -
2020
TELEPHONE [phone]E-MAIL
sales_at_researchbeam.com
Published on Oct 2014
2


Report Overview

• Scope
• The report provides a snapshot of the global
  therapeutic landscape of Epidermolysis Bullosa
• The report reviews key pipeline products under
  drug profile section which includes, product
  description, MoA and RD brief, licensing and
  collaboration details other developmental
  activities
• The report reviews key players involved in the
  therapeutics development for Epidermolysis
  Bullosa and enlists all their major and minor
  projects
• The report summarizes all the dormant and
  discontinued pipeline projects
• A review of the Epidermolysis Bullosa products
  under development by companies and
  universities/research institutes based on
  information derived from company and
  industry-specific sources
• Pipeline products coverage based on various
  stages of development ranging from
  pre-registration till discovery and undisclosed
  stages
• A detailed assessment of monotherapy and
  combination therapy pipeline projects
• Coverage of the Epidermolysis Bullosa pipeline on
  the basis of target, MoA, route of administration
  and molecule type - Latest news and deals
  relating related to pipeline products
• Read More At http//www.researchbeam.com/epiderm
  olysis-bullosa-pipeline-review-h1-2015-market

3


Table of Content
Table of Contents 2List of Tables 4List of
Figures 5Introduction 6Global Markets Direct
Report Coverage 6Epidermolysis Bullosa Overview
7Therapeutics Development 8Pipeline Products
for Epidermolysis Bullosa - Overview 8Pipeline
Products for Epidermolysis Bullosa - Comparative
Analysis 9Epidermolysis Bullosa - Therapeutics
under Development by Companies 10Epidermolysis
Bullosa - Therapeutics under Investigation by
Universities/Institutes 11Epidermolysis Bullosa
- Pipeline Products Glance 12Late Stage Products
12Clinical Stage Products 13Early Stage
Products 14Epidermolysis Bullosa - Products
under Development by Companies 15Epidermolysis
Bullosa - Products under Investigation by
Universities/Institutes 16Epidermolysis Bullosa
- Companies Involved in Therapeutics Development
17Fibrocell Science, Inc. 17GlaxoSmithKline plc
18InMed Pharmaceuticals Inc. 19RegeneRx
Biopharmaceuticals, Inc. 20
4


Report Overview

• Reasons to buy
• Provides strategically significant competitor
  information, analysis, and insights to formulate
  effective RD development strategies
• Identify emerging players with potentially strong
  product portfolio and create effective
  counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding
  the focus areas of leading companies
• Identify and understand important and diverse
  types of therapeutics under development for
  Epidermolysis Bullosa
• Plan mergers and acquisitions effectively by
  identifying key players of the most promising
  pipeline
• Devise corrective measures for pipeline projects
  by understanding Epidermolysis Bullosa pipeline
  depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing
  strategies by identifying prospective partners
  with the most attractive projects to enhance and
  expand business potential and Scope
• Modify the therapeutic portfolio by identifying
  discontinued projects and understanding the
  factors that drove them from pipeline
• Enquire At http//www.researchbeam.com/epidermol
  ysis-bullosa-pipeline-review-h1-2015-market/enquir
  e-about-report

5



FOR MORE DETAILS
Visit us at
http//www.researchbeam.com/epidermolysis-bullosa-
pipeline-review-h1-2015-market
Stay With Us
5933 NE Win Sivers Drive,205, Portland, OR
97220United States
TELEPHONE [phone] DIRECT 1 (503)
894-6022E-MAIL sales_at_researchbeam.com